Skip to main content

Table 2 Significant prognostic factors for survivals in a cohort of newly-diagnosed patients with acute promyelocytic leukaemia

From: Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021

  

Univariate analysis

   

Multivariate analysis

  

Parameters

Number

HR

95% C.I.

P value

 

H.R.

95% C.I.

P value

30-day survival (N = 751)

        

Sex

        

 Male

364

1.60

1.15–2.24

0.005

 

1.48

1.05–2.09

0.03

 Female

387

0.62

0.45–0.87

  

0.68

0.48–0.95

 

Age

        

 ≤ 50 years

471

0.51

0.37–0.70

< 0.001

 

0.37

0.26–0.53

< 0.001

 > 50 years

280

1.96

1.42–2.72

  

2.71

1.91–3.86

 

Period of diagnosis

        

 1991–1999

146

1.90

1.25–2.89

0.008

 

1.96

1.23–3.12

0.02

 2000–2009

257

1.49

1.02–2.18

  

1.27

0.85–1.89

 

 2010–2021

348

0.53

0.35–0.80

  

0.51

0.32–0.81

 

Leucocyte count

        

 ≤ 10 × 109/L

481

0.33

0.23–0.46

< 0.001

 

0.32

0.23–0.45

< 0.001

 > 10 × 109/L

253

3.09

2.20–4.32

  

3.14

2.23–4.43

 

Induction regimens

        

 ATRA-based

613

6.86

2.81–16.73

< 0.001

 

6.14

2.44–15.43

< 0.001

 Oral-ATO-based

138

0.15

0.06–0.36

  

0.16

0.07–0.41

 

Overall survival (N = 751)

        

Sex

        

 Male

364

1.47

1.16–1.89

0.001

 

1.35

1.06–1.72

0.015

 Female

387

0.68

0.53–0.86

  

0.74

0.58–0.94

 

Age

        

 ≤ 50 years

471

0.49

0.39–0.62

< 0.001

 

0.35

0.27–0.45

< 0.001

 > 50 years

280

2.04

1.61–2.60

  

2.88

2.23–3.73

 

Leucocyte count

        

 ≤ 10 × 109/L

481

0.51

0.40–0.65

< 0.001

 

0.51

0.39–0.65

< 0.001

 > 10 × 109/L

253

1.98

1.55–2.52

  

1.98

1.54–2.54

 

Sanz score

        

 Low-risk

142

0.66

0.47–0.91

< 0.001

 

1.59

1.12–2.24

0.01

 Intermediate-risk

340

0.44

0.33–0.57

  

0.63

0.45–0.89

 

 High-risk

253

1.53

1.10–2.11

  

1.98

1.54–2.54

 

Treatment regimens

        

 ATRA-based

469

5.26

3.57–7.69

< 0.001

 

5.56

3.84–8.33

< 0.001

 Oral-ATO-based

282

0.19

0.13–0.28

  

0.18

0.12–0.26

 

Post-30-day survival (N = 607)

        

Age

        

 ≤ 50 years

402

0.45

0.31–0.64

< 0.001

 

0.29

0.20–0.43

< 0.001

 > 50 years

205

2.23

1.57–3.17

  

3.40

2.33–4.98

 

Treatment regimens

        

 ATRA-based

331

2.94

1.92–4.55

< 0.001

 

3.03

1.82–5.26

< 0.001

 Oral-ATO-based

276

0.34

0.22–0.52

  

0.33

0.19–0.55

 

Relapse free survival (N = 607)

        

Period of diagnosis

        

 1991–1999

107

4.38

2.34–8.16

< 0.001

 

2.51

1.27–4.99

< 0.001

 2000–2009

203

4.52

2.58–7.90

  

3.40

1.90–6.09

 

 2010–2021

297

0.23

0.12–0.43

  

0.40

0.25–0.73

 

Treatment regimens

        

 ATRA-based

331

3.45

2.13–5.56

< 0.001

 

2.33

1.37–4.00

0.002

 Oral-ATO-based

276

0.29

0.18–0.47

  

0.43

0.25–0.73

 
  1.  h: hazard ratio; C.I.: confidence interval; ATRA: all trans retinoic acid; ATO: arsenic trioxide